Abstract
Hepatitis B virus (HBV) reactivation was reported to be induced by transcatheter arterial chemoembolization (TACE) in HBV-related hepatocellular carcinonma (HCC) patients with a high incidence. The effective strategy to reduce hepatitis flares due to HBV reactivation in this specific group of patients was limited to lamivudine. This retrospective study was aimed to investigate the efficacy of prophylactic entecavir in HCC patients receiving TACE. A consecutive series of 191 HBV-related HCC patients receiving TACE were analyzed including 44 patients received prophylactic entecavir. Virologic events, defined as an increase in serum HBV DNA level to more than 1 log10 copies/ml higher than nadir the level, and hepatitis flares due to HBV reactivation were the main endpoints. Patients with or without prophylactic were similar in host factors and the majorities of characteristics regarding to tumor factors, HBV status, liver function and LMR. Notably, cycles of TACE were parallel between the groups. Ten (22.7%) patients receiving prophylactic entecavir reached virologic response. The patients receiving prophylactic entecavir presented significantly reduced virologic events (6.8% vs 54.4%, p=0.000) and hepatitis flares due to HBV reactivation (0.0% vs 11.6%, p=0.039) compared with patients without prophylaxis. Kaplan-Meier analysis illustrated that the patients in the entecavir group presented significantly improved virologic events free survival (p=0.000) and hepatitis flare free survival (p=0.017). Female and Eastern Cooperative Oncology Group (ECOG) performance status 2 was the only significant predictors for virological events in patients without prophylactic antiviral. Rescue antiviral therapy did not reduce the incidence of hepatitis flares due to HBV reactivation. Prophylactic entecavir presented promising efficacy in HBV-related cancer patients receiving TACE. Lower performance status and female gender might be the predictors for HBV reactivation in these patients.
Highlights
Hepatitis B virus (HBV) reactivation in patients receiving systemic chemotherapy has been profoundly investigated in recent years (Li et al, 2010; Torres and Davila, 2012; Wu et al, 2013; Yeo and Chan, 2013; Li et al, 2014)
The patients receiving prophylactic entecavir presented significantly reduced virologic events (6.8% vs 54.4%, p=0.000) and hepatitis flares due to HBV reactivation (0.0% vs 11.6%, p=0.039) compared with patients without prophylaxis
The effective strategy to reduce hepatitis flares due to HBV reactivation for hepatocellular carcinonma (HCC) patients receiving transcatheter arterial chemoembolization (TACE) was limited to lamivudine (Nagamatsu et al, 2004; Jang et al, 2006)
Summary
Hepatitis B virus (HBV) reactivation in patients receiving systemic chemotherapy has been profoundly investigated in recent years (Li et al, 2010; Torres and Davila, 2012; Wu et al, 2013; Yeo and Chan, 2013; Li et al, 2014) It has not been fully evaluated in HBV-related hepatocellular carcinonma (HCC) patients receiving Transcatheter arterial chemoembolization (TACE) due to limited sample size and amount of studies (Vizzini et al, 2003; Jang et al, 2004; Park et al, 2005; Jang et al, 2006; Peng et al, 2012). The effective strategy to reduce hepatitis flares due to HBV reactivation in this specific group of patients was limited to lamivudine This retrospective study was aimed to investigate the efficacy of prophylactic entecavir in HCC patients receiving TACE.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
